Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitors.
G D Hartman, M E Duggan, W F Hoffman, R J Meissner, J J Perkins, A E Zartman, A M Naylor-Olsen, J J Cook, J D Glass, R J Lynch, G Zhang, R J Gould
Index: Bioorg. Med. Chem. Lett. 9(6) , 863-8, (1999)
Full Text: HTML
Abstract
A new series of potent, linearly-minimized, orally active, selective GPIIb/IIIa inhibitors is identified. Thus 15 (L-750,034) achieves interaction via a constrained, non-turned conformation that maintains the proper distance between its charged termini and full sulfonamide exosite interaction. The diminutive stature and the proposed linear conformation of L-750,034 define a new paradigm for the conceptualization of RGD mimics.
Related Compounds
Related Articles:
2015-08-20
[J. Phys. Chem. B 119 , 10466-77, (2015)]
1997-01-17
[J. Med. Chem. 40(2) , 226-35, (1997)]
2008-10-09
[J. Phys. Chem. A 112(40) , 10029-39, (2008)]
2014-12-18
[Eur. J. Pharm. Sci. 65 , 56-64, (2014)]
1996-08-01
[Protein Sci. 5(8) , 1502-11, (1996)]